Exacerbación aguda de la enfermedad pulmonar obstructiva crónica por infección en una paciente con estadio Gold IV
DOI:
https://doi.org/10.29166/ciencias_medicas.v42i2.1507Palabras clave:
enfermedad pulmonar obstructiva crónica, infección bacteriana, complicación, terapia actual, tabaquismoResumen
La enfermedad pulmonar obstructiva crónica se caracteriza por obstrucción del flujo respiratorio en ocasiones no reversible en su totalidad; generalmente, la obstrucción sigue una evolución progresiva y se asocia a una reacción inflamatoria pulmonar patológica ante gases tóxicos o partículas1,2. La exacerbación
aguda subsecuente a una infección reviste como complicación, gravedad que puede comprometer la vida del paciente. El reporte de caso versa sobre una paciente de 68 años de edad con enfermedad pulmonar obstructiva crónica (EPOC) diagnosticada, que se complica por un proceso infeccioso bacteriano agudo que amerita su ingreso a cuidados intensivos (UCI) y el empleo de una terapia compleja. En el texto se detalla aspectos diagnósticos, terapéuticos y la evolución; se complementa con un análisis de las terapias actuales recomendadas por directrices internacionales, debate nuevos esquemas terapéuticos e insiste en el abandono del hábito tabáquico ante un cuadro de EPOC
Descargas
Métricas
Citas
Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airways obstruction in chronic obstructive lung disease. N Engl J Med1968; 278:1355–60
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2017.
Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic bstructive pulmonary disease in the USA. ClinicoEconomics and Outcomes Research: CEOR. 2013; 5:235-245.
World Health Organization. Fact Sheet Nº310: The top 10 causes of death. 2014.
Ko, F. W., Chan, K. P., Hui, D. S., Goddard, J. R., Shaw, J. G., Reid, D. W., and Yang, I. A. Acute exacerbation of COPD. Respirology 2016; doi: 10.1111/resp.12780.
Sapey E, Stockley RA. COPD exacerbations 2: Aetiology. Thorax. 2006; 61(3):250-258.
Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Therapeutic Advances in Chronic Disease. 2014; 5(5):212-227.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et. al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 15.September 2007; 176(6):532–55.
Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives Dave Singh. British Journal of Clinical Pharmacology. 2015; 79(5):695-708.
Falk JA, Minai OA, Mosenifar Z. Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society. 2008; 5(4):506-512.
Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 11.
Ram FS, Jardin JR, Atallah A, et al. Efficacy of theophylline in people with table chronic obstructive pulmonary disease: a systematic review and meta- analysis. Respir Med 2005; 99:135.
Poole PJ. Role of mucolytics in the management of COPD. International Journal of C h r o n i c Obstructive Pulmonary Disease. 2006; 1(2):123-128.
Stockley RA, Miravitlles M, Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet Journal of Rare Diseases. 2013; 8:149.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket Guide to COPD Diagnosis, Mangement, and Prevention, 2016.
Martinez FJ, Calverley PM, GoehringUM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015; 9971: 857–866.
Aaron SD. Management and prevention of exacerbations of COPD. BMJ. 2014; 349: g5237.
Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; CD006897.
López-Campos JL, Calero Acuña C. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease? Expert Review of Respiratory Medicine Vol. 7, Iss. sup2, 2013.
Lococo F, Cesario A, Del Bufalo A, Ciarrocchi A, Prinzi G, Mina M, Bonassi S, Russo P. Novel therapeutic strategy in the management of COPD: a systems medicine approach. Curr Med Chem. 2015; 22(32):3655-75.
Bonten T., Kasteleyn M., Taube C., Chavannes N. The clinical management of COPD exacerbations: an update. Expert Review of Clinical Pharmacology Vol. 9, Iss. 2, 2016.
Sasaki H, Sekizawa K, Yanai M, Arai H, Yamaya M, Ohrui T. Effects of air pollution and smoking on chronic obstructive pulmonary disease and bronchial asthma.Tohoku J Exp Med. 1998 Nov; 186(3):151-67.
Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study. International Journal of Chronic Obstructive Pulmonary Disease. 2009; 4:137-148.
Laniado - Laborín R. Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century. International Journal of Environmental Research and Public Health. 2009; 6(1):209-224.
Lewis A, Torvinen S, Dekhuijzen PNR, et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Services Research. 2016; 16:251.
Menezes AMB, Perez-Padilla R, Hallal PC, Jardim JR, Muiño A, Lopez MV, et al., for the PLATINO Team Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int. J. Tuberc. Lung Dis. 2008; 12:709–712.
Laniado - Laborín R. Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century. International Journal of Environmental Research and Public Health. 2009; 6(1):209-224.
